Helicobacter pylori (H. pylori) is the causal agent of chronic gastritis, ulcer and gastric cancer. It has the potential to persist in the human stomach for decades, sometimes causing neither harm nor clinical symptoms. Nevertheless, on some occasions, depending on the host immune system and the strain causing the infection, the outcome can be very serious. To maintain the infection, the bacterium must adapt to survive the host defences. One way to accomplish this is to sequentially change the external proteins on the bacterial surface.
A research article to be published on January 21, 2010 in the World Journal of Gastroenterology addresses this topic. As part of a search for adequate antigens to generate a vaccine against H. pylori, a group lead by Dr. Alejandro Venegas studied 2 potential targets, HopE and HopV outer membrane proteins, which function as porins. The study revealed that out of 130 H. pylori strains, 60 and 82 of them possessed the hopE and hopV genes, respectively, but only 16 and 9 actually expressed them and synthesized the respective proteins. In other words, 73% and 90% of the hopE and hopV detected genes were turned off. In addition, roughly 10% of H. pylori-infected patients develop immunoreactivity against HopV or HopE, which confirms the low number of strains expressing them. These proteins are part of a larger family, with which they share sequence homology, so their genes are redundant. These genes could be turned alternatively on and off, and this strategy may allow the bacteria to display, at the same time, different external proteins and distract the immune system by directing its attacks to proteins which will be replaced again as needed.
This study provides some understanding of one of the mechanisms the persistent bacteria H. pylori uses to evade the immune system. The authors' efforts have been oriented to generate a vaccine against H. pylori, and although HopE and HopV are too infrequently expressed in clinical strains and so are not ideal candidate as antigens, they induce a good immune response (as tested in rabbits) and could be used in combination with other proteins in a multivalent vaccine. More research is needed to determine a strong immunogenic epitope or group of epitopes to direct the immune response towards H. pylori outer membrane proteins.
Reference: Lienlaf M, Morales JP, Díaz MI, Díaz R, Bruce E, Siegel F, León G, Harris PR, Venegas A. Helicobacter pylori HopE and HopV porins present scarce expression among clinical isolates. World J Gastroenterol 2010; 16(3): 320-329
Telephone: +56-2-6862661 Fax: +56-2-2225515
About World Journal of Gastroenterology
World Journal of Gastroenterology (WJG), a leading international journal in gastroenterology and hepatology, has established a reputation for publishing first class research on esophageal cancer, gastric cancer, liver cancer, viral hepatitis, colorectal cancer, and H pylori infection and provides a forum for both clinicians and scientists. WJG has been indexed and abstracted in Current Contents/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch) and Journal Citation Reports/Science Edition, Index Medicus, MEDLINE and PubMed, Chemical Abstracts, EMBASE/Excerpta Medica, Abstracts Journals, Nature Clinical Practice Gastroenterology and Hepatology, CAB Abstracts and Global Health. ISI JCR 2008 IF: 2.081. WJG is a weekly journal published by WJG Press. The publication dates are the 7th, 14th, 21st, and 28th day of every month. WJG is supported by The National Natural Science Foundation of China, No. 30224801 and No. 30424812, and was founded with the name of China National Journal of New Gastroenterology on October 1, 1995, and renamed WJG on January 25, 1998.